[1] Wang Z Y, Zhang D S.The advance in research of nanomedicine [J].Journal of Southeast University (Medical Science Edition), 2004, 23(2):131-135.(in Chinese)
[2] Zhang P, Wang S Y, Hu L H, et al.Treatment of acute promyelocytic leukemia with intravenous arsenic trioxide [J].Chinese Journal of Hematology, 1996, 17:58-60.(in Chinese)
[3] Jing Y, Xia L, Waxman S.Targeted removal of PML-RARalpha protein is required prior to inhibition of histone deacetylase for overcoming all-trans retinoic acid differentiation resistance in acute promyelocytic leukemia [J].Blood, 2002, 100(3):1008-1013.
[4] Woo S H, Park I C, Park M J, et al.Arsenic trioxide induces apoptosis through a reactive oxygen species-dependent pathway and loss of mitochondrial membrane potential in HeLa cells [J].International Journal of Oncology, 2002, 21(1):57-63.
[5] Shen Z Y, Shen J, Cai W J, et al.The alteration of mitochondria is an early event of arsenic trioxide induced apoptosis in esophageal carcinoma cells [J].International Journal of Molecular Medicine, 2000, 5(2):155-158.
[6] Zhang T C, Cao E H, Li J F, et al.Induction of apoptosis and inhibition of human gastric cancer MGC-803 cell growth by arsenic trioxide [J].European Journal of Cancer, 1999, 35(8):1258-1263.
[7] Du C W, Li D R, Lin Y C, et al.Arsenic trioxide induces differentiation of human nasopharyngeal carcinoma in BALB/C nude mice xenograft model [J].Chinese Journal of Cancer, 2003, 22(1):21-25.(in Chinese)
[8] Yu D, Wang Z H, Cheng S B, et al.The effect of arsenic trioxide on the expression of Hsc and HNF4 in nuclear matrix proteins in HepG2 cells [J].Anticancer Research, 2001, 21(4A):2553-2559.
[9] Uslu R, Sanli U A, Sezgin C, et al.Arsenic trioxide-mediated cytotoxicity and apoptosis in prostate and ovarian carcinoma cell lines [J].Clinical Cancer Research, 2000, 6(12):4957-4964.
[10] Baj G, Arnulfo A, Deaglio S, et al.Arsenic trioxide and breast cancer:analysis of the apoptotic, differentiative and immunomodulatory effects [J].Breast Cancer Research and Treatment, 2002, 73(1):61-73.
[11] Zhou D F.Generality of materials[M].Beijing:Chemical Industry Press, 2001.(in Chinese)
[12] Sithinamsuwan P, Piratvisuth T, Tanomkiat W, et al.Review of 336 patients with hepatocellular carcinoma at Songklanagarind Hospital [J].World Journal of Gastroenterology, 2000, 6(3):339-343.
[13] Tang Z Y.Hepatocellular carcinoma:cause, treatment and metastasis [J].World Journal of Gastroenterology, 2001, 7:445-454.
[14] Miller Wilson H Jr, Schipper Hyman M, Lee J S, et al.Mechanisms of action of arsenic trioxide [J].Cancer Research, 2002, 62(14):3893-3903.
[15] Huang S Y, Chang C S, Tang J L, et al.Acute and chronic arsenic poisoning associated with treatment of acute promyelocytic leukaemia [J].British Journal of Haematology, 1998, 103(4):1092-1095.
[16] Hu X, Ma L, Hu N, et al.Ailing No.1 in treating 62 cases of acute promyelocytic leukaemia [J].Chinese Journal of Integrated Traditional and Western Medicine, 1999, 19(8):473-476.(in Chinese)
[17] Dong J T, Luo X M.Effects of arsenic on DNA damage and repair in human fetal lung fibroblasts [J].Mutation Research, 1994, 315:11-15.
[18] Tsai S M, Wang T N, Ko Y C, et al.Mortality for certain disease in areas with high levels of arsenic in drinking water [J].Archives of Environmental Health, 1999, 54(3):186-193.
[19] Jung T, Kamm W, Breitenbach A, Kaiserling E, et al.Biodegradable nanoparticles for oral delivery of peptides:is there a role for polymers to affect mucosal uptake?[J].European Journal of Pharmaceutics and Biopharmaceutics, 2000, 50(1):147-160.
[20] Ma M, Zhu Y, Zhang Y, et al.Preparation of magnetite nanoparticles and interaction with cancer cells [J].Journal of Southeast University(Natural Science Edition), 2003, 33(2):205-207.(in Chinese)
[21] Zhang D S, Fan X S, Jia X P, et al.Effect of nano-magnetoliposomes containing arsenic trioxide on hela cells [J].Chinese Journal of Traditional and Western Medicine, 2003, 4(9):1289-1292.
[22] Ying D, Xu Huibi, Huang Kaixun, et al.Size effects of realgar particles on apoptosis in a human umbilical vein endothelial cell line:ECV-304 [J].Pharmacological Research, 2001, 44(6):513-518.